In a model of HER2+/neu breast tumor xenograft, it was indeed shown that an anti-HER2/neu engineered antibody lacking the ability to bind FcγRIIIa was inefficient to prevent tumor growth, suggesting a potential role of NK in mAb efficacy [104]. This evidence concerns the gene ERBB2 and breast neoplasm.